Jubilant Pharmova Q3 Profit Halves Despite Revenue Growth; Stock Dips

• Jubilant Pharmova's Q3 consolidated profit dropped to ₹56 crore from ₹101 crore year-on-year.
• Consolidated revenue increased from ₹1821 crore to ₹2123 crore.
• EBITDA rose to ₹290 crore, but EBITDA margin declined from 15.4% to 13.6%.
• Shares closed down 1.68% at ₹957.45 on February 6, with a 52-week high of ₹1,248.
• The company has a market cap of approximately ₹15.16 thousand crore and a P/E ratio of 31.84.